© The Author 2006. Published by Oxford University Press.
ARTICLE |
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Affiliations of authors: Department of Urology, University of Texas Health Science Center, San Antonio, TX (IMT); The Fred Hutchinson Cancer Research Center, Seattle, WA (DPA, CC, PJG, CMT, ZF); University of Colorado, Denver, CO (MSL); Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (HLP); Southwest Oncology Group, San Antonio, TX (CAC)
Correspondence to: Ian Thompson, MD, Department of Urology, UTHSCSA, University of Texas HSC at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229 (e-mail: thompsoni{at}uthscsa.edu).
Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. Methods: We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy, had at least one PSA measurement and a digital rectal examination (DRE) performed during the year before the biopsy, and had at least two PSA measurements performed during the 3 years before the prostate biopsy. Logistic regression was used to model the risk of prostate cancer and high-grade disease associated with age at biopsy, race, family history of prostate cancer, PSA level, PSA velocity, DRE result, and previous prostate biopsy. Risk equations were created from the estimated logistic regression models. All statistical tests were two-sided. Results: A total of 1211 (21.9%) men were diagnosed with prostate cancer by prostate biopsy. Variables that predicted prostate cancer included higher PSA level, positive family history of prostate cancer, and abnormal DRE result, whereas a previous negative prostate biopsy was associated with reduced risk. Neither age at biopsy nor PSA velocity contributed independent prognostic information. Higher PSA level, abnormal DRE result, older age at biopsy, and African American race were predictive for high-grade disease (Gleason score 
7) whereas a previous negative prostate biopsy reduced this risk. Conclusions: This predictive model allows an individualized assessment of prostate cancer risk and risk of high-grade disease for men who undergo a prostate biopsy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Vener, C. Derecho, J. Baden, H. Wang, Y. Rajpurohit, J. Skelton, J. Mehrotra, S. Varde, D. Chowdary, W. Stallings, et al. Development of a Multiplexed Urine Assay for Prostate Cancer Diagnosis Clin. Chem., May 1, 2008; 54(5): 874 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Wilt Commentary: controversies in NICE guidance on prostate cancer BMJ, March 15, 2008; 336(7644): 612 - 614. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hemminki, J. Sundquist, and J. Lorenzo Bermejo Familial Risks for Cancer as the Basis for Evidence-Based Clinical Referral and Counseling Oncologist, March 1, 2008; 13(3): 239 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. D'Amico Prostate-Specific Antigen (PSA) and PSA Velocity: Competitors or Collaborators in the Prediction of Curable and Clinically Significant Prostate Cancer J. Clin. Oncol., February 20, 2008; 26(6): 823 - 824. [Full Text] [PDF]
|
|
|
|
|
|
D. Ulmert, A. M. Serio, M. F. O'Brien, C. Becker, J. A. Eastham, P. T. Scardino, T. Bjork, G. Berglund, A. J. Vickers, and H. Lilja Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened Population J. Clin. Oncol., February 20, 2008; 26(6): 835 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Connolly, A. Black, A. Gavin, P. F. Keane, and L. J. Murray Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Pepe, Z. Feng, Y. Huang, G. Longton, R. Prentice, I. M. Thompson, and Y. Zheng Integrating the Predictiveness of a Marker with Its Performance as a Classifier Am. J. Epidemiol., February 1, 2008; 167(3): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Etzioni, D. P. Ankerst, N. S. Weiss, L. Y. T. Inoue, and I. M. Thompson Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence J Natl Cancer Inst, October 17, 2007; 99(20): 1510 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Parekh, D. P. Ankerst, J. Baillargeon, B. Higgins, E. A. Platz, D. Troyer, J. Hernandez, R. J. Leach, A. Lokshin, and I. M. Thompson Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1966 - 1972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Ross and P. W. Kantoff Predicting Outcomes in Prostate Cancer: How Many More Nomograms Do We Need? J. Clin. Oncol., August 20, 2007; 25(24): 3563 - 3564. [Full Text] [PDF]
|
|
|
|
|
|
R. K. Nam, A. Toi, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, S. Appu, D. A. Loblaw, L. Sugar, S. A. Narod, and M. W. Kattan Assessing Individual Risk for Prostate Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3582 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Thompson, D. Pauler Ankerst, C. Chi, P. J. Goodman, C. M. Tangen, S. M. Lippman, M. S. Lucia, H. L. Parnes, and C. A. Coltman Jr Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial J. Clin. Oncol., July 20, 2007; 25(21): 3076 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Thompson and D. P. Ankerst Prostate-specific antigen in the early detection of prostate cancer Can. Med. Assoc. J., June 19, 2007; 176(13): 1853 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Lee, T Lim, J. Uhm, K. Park, S. Park, S. Lee, J. Park, Y. Park, H. Lim, T. Sohn, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Ann. Onc., May 1, 2007; 18(5): 886 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Parekh, D. P. Ankerst, and I. M. Thompson Prostate-Specific Antigen Levels, Prostate-Specific Antigen Kinetics, and Prostate Cancer Prognosis: A Tocsin Calling for Prospective Studies J Natl Cancer Inst, April 4, 2007; 99(7): 496 - 497. [Full Text] [PDF]
|
|
|
|
|
|
R. D. Etzioni, D. P. Ankerst, and I. M. Thompson Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability J Natl Cancer Inst, March 21, 2007; 99(6): 489 - 490. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter, L. Ferrucci, A. Kettermann, P. Landis, J. Wright, J. I. Epstein, B. J. Trock, and E. J. Metter Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability J Natl Cancer Inst, March 21, 2007; 99(6): 490 - 490. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Marrelli and F. Roviello Prognostic Score in Gastric Cancer Patients Ann. Surg. Oncol., February 1, 2007; 14(2): 362 - 364. [Full Text] [PDF]
|
|
|
|
|
|
T. J Wilt and I. M Thompson Clinically localised prostate cancer BMJ, November 25, 2006; 333(7578): 1102 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter Assessing risk: does this patient have prostate cancer? J Natl Cancer Inst, April 19, 2006; 98(8): 506 - 507. [Full Text] [PDF]
|
|